Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed pancreatic cancer;~2. Unresectable locally advanced or metastatic disease ;~3. Documented disease progression after first-line treatment gemcitabine based therapy~4. ECOG: 0-1;~5. Adequate organ and bone marrow function;~6. sign an informed consent.~Exclusion Criteria:~1. Active CNS metastasis;~2. Uncontrolled tumor-related pain;~3. Clinically significant GI disorders;~4. Significant cardiovascular disease;~5. Active infection or uncontrolled fever;~6. Pregnant or breast feeding patients;~7. Allergic to a drug ingredient or component;~8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group A (Type: EXPERIMENTAL): Irinotecan liposome plus 5-fluorouracil, Leucovorin
- Treatment group B (Type: ACTIVE_COMPARATOR): Placebo plus 5-fluorouracil, Leucovorin

Based on this trial design, predict the completion outcome and termination type (if applicable).